89bio Inc (ETNB)
7.70
-0.75
(-8.88%)
USD |
NASDAQ |
Jun 26, 10:40
89bio SG&A Expense (TTM): 32.60M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 32.60M |
December 31, 2023 | 28.97M |
September 30, 2023 | 27.66M |
June 30, 2023 | 24.57M |
March 31, 2023 | 22.41M |
December 31, 2022 | 21.45M |
September 30, 2022 | 20.42M |
June 30, 2022 | 20.20M |
March 31, 2022 | 20.06M |
December 31, 2021 | 19.41M |
Date | Value |
---|---|
September 30, 2021 | 17.93M |
June 30, 2021 | 16.53M |
March 31, 2021 | 14.84M |
December 31, 2020 | 13.16M |
September 30, 2020 | 11.80M |
June 30, 2020 | 10.09M |
March 31, 2020 | 7.695M |
December 31, 2019 | 5.294M |
September 30, 2019 | 3.591M |
June 30, 2019 | 2.57M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
2.57M
Minimum
Jun 2019
32.60M
Maximum
Mar 2024
17.06M
Average
18.67M
Median
SG&A Expense (TTM) Benchmarks
ACADIA Pharmaceuticals Inc | 413.31M |
Alnylam Pharmaceuticals Inc | 822.78M |
Savara Inc | 17.94M |
Madrigal Pharmaceuticals Inc | 172.76M |
Aldeyra Therapeutics Inc | 10.98M |